Regulated information
Nazareth (
Strong operational performance in Latin and
Highlights of Q1-2021
- Reported turnover decreased 4.8% on sharply weaker BRL, USD and MXN versus EUR
- Turnover growth of 4.9% at constant exchange rates
- Strong operational performance in
North and Latin America despite fewer doctor’s visits and postponement of elective care - Strong COVID-19 related decrease of prescriptions impacted performance in EMEA
- Wichita compounding facility on track; successful product launches offset lower demand due to COVID-19
- Transition to new repackaging facility in
Poland to start in second half of April
In almost all the countries where we are active elective care was scaled back and doctor’s visits were postponed, resulting in a decline in prescriptions across the market. This was clearly visible in EMEA in particular, where the number of prescriptions in the first quarter was lower not only compared to last year’s level but also compared to the fourth quarter of 2020. This mainly affected Compounding Services and Essentials. In the earlier stages of the pandemic, this effect was offset by an increase in demand for COVID-19-related products, however this was not the case during the quarter under review because the health sector is now better equipped to deal with the situation.
The development outlined above resulted in a decline in turnover of more than 7% in EMEA. Thanks to our strong product portfolio and positioning, Fagron EMEA will be able to benefit once measures are eased and the number of prescriptions starts to increase. Moreover, we have taken more steps in EMEA to further increase the organization’s efficiency. The transition of activities to the new GMP facility in
Fagron Latin America realized strong organic growth of 21% at constant exchange rates. Although the countries where
All around the world vaccination programs will enable further relaxation of the restrictive measures, but the pace at which this is happening varies widely from region to region. This means that visibility continues to be limited by COVID-19. Our strong focus area’s – prevention, lifestyle and outsourcing of sterile compounding activities by hospitals - have become even more relevant as a result of the pandemic. Together with a more focused organization and further expansion of the product portfolio this means that we are in an excellent position to benefit once the health sector returns to normal levels. We reiterate our expectation for growth in both turnover and profitability for the full year 2021.”
Please open the link below for the press release:
© OMX, source